This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Darlene N. Jody, MD
Bristol-Myers Squibb Co Princeton, NJ

JAMA. 1997;277(4):296-297.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—To our knowledge, this is the first report of these adverse events associated with concomitant use of simvastatin and nefazodone. Since simvastatin is thought to be metabolized by cytochrome P-450 3A4 (CYP3A4),¹ an increased likelihood of these adverse events might be expected if simvastatin is coadministered with any agent that inhibits the activity of the CYP3A4 isoenzyme (eg, nefazodone, fluvoxamine, fluoxetine, sertraline, grapefruit juice, erythromycin, ketoconazole, or itraconazole).² In addition, myositis and rhabdomyolysis are adverse events associated with simvastatin monotherapy. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?